Search Results - "Pellen, Daniel"

The development of a Youth Psychiatry specialty within the RANZCP (‘the College') by Pellen, Daniel

“…Objective To describe the development of a Youth Psychiatry specialty within the College. Conclusion Progress has been frustratingly slow. The recognition of a…”
Get full text

Psychiatry research in the COVID-19 era and beyond: A role for mathematical models by Waters, Edward K, Pellen, Daniel, Buus, Niels

Get full text

Adjunctive canakinumab reduces peripheral inflammation markers and improves positive symptoms in people with schizophrenia and inflammation: A randomized control trial by Weickert, Thomas W, Jacomb, Isabella, Lenroot, Rhoshel, Lappin, Julia, Weinberg, Danielle, Brooks, William S, Brown, David, Pellen, Daniel, Kindler, Jochen, Mohan, Adith, Wakefield, Denis, Lloyd, Andrew R, Stanton, Clive, O'Donnell, Maryanne, Liu, Dennis, Galletly, Cherrie, Shannon Weickert, Cynthia

“…Clinical trials of anti-inflammatories in schizophrenia do not show clear and replicable benefits, possibly because patients were not recruited based on…”
Get full text

A certificate in youth psychiatry: meeting the training needs of psychiatrists by Macmillan, Iain, Thompson, Andrew, Kalucy, Megan, Pellen, Daniel, Killackey, Eóin, McGorry, Patrick, Scott, James G

“…Objective: This paper provides the rationale for the development of sub-specialty training in youth psychiatry. Method: Training needs for youth psychiatry are…”
Get full text

The value of early intervention in creating the new mental health system: Response to Allison et al by Chanen, Andrew, Yung, Alison, Killackey, Eoin, Hickie, Ian, Coghill, David, Scott, James G, Scott, Elizabeth, Denborough, Paul, Dixon, Lisa, Fisher, Leeanne, Kane, John, Malla, Ashok, Nordentoft, Merete, Pellen, Daniel, Radovini, Alessandra, McGorry, Patrick

Get full text

107. Reduction in Peripheral C-Reactive Protein Levels With Canakinumab Administration is Related to Reduced Positive Symptom Severity in Patients With Schizophrenia and Inflammation by Weickert, Thomas, Jacomb, Isabella, Lenroot, Rhoshel, Lappin, Julia, Weinberg, Danielle, Brooks, William, Brown, David, Pellen, Daniel, Kindler, Jochen, Mohan, Adith, Wakefield, Denis, Lloyd, Andrew, Stanton, Clive, O'Donnell, Maryanne, Liu, Dennis, Galletly, Cherrie, Weickert, Cynthia Shannon

Get full text

S33. REDUCTION IN PERIPHERAL C-REACTIVE PROTEIN LEVELS WITH CANAKINUMAB ADMINISTRATION IS RELATED TO REDUCED POSITIVE SYMPTOM SEVERITY IN PATIENTS WITH SCHIZOPHRENIA AND INFLAMMATION by Weickert, Thomas, Jacomb, Isabella, Lenroot, Rhoshel, Lappin, Julia, Weinberg, Danielle, Brooks, William, Brown, David, Pellen, Daniel, Kindler, Jochen, Mohan, Adith, Wakefield, Denis, Lloyd, Andrew, Stanton, Clive, O’Donnell, Maryanne, Liu, Dennis, Galletly, Cherrie, Weickert, Cynthia Shannon

“…Abstract Background Schizophrenia is characterized by positive and negative symptoms and cognitive deficits related to functional disability. Approved…”
Get full text